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Abstract
DNA methylation patterns are frequently deregulated in t(8;21)
acute myeloid leukaemia (AML), but little is known of the mecha-
nisms by which specific gene sets become aberrantly methylated.
Here, we found that the promoter DNA methylation signature of
t(8;21)+ AML blasts differs from that of t(8;21) AMLs. This study
demonstrated that a novel hypermethylated zinc finger-containing
protein, THAP10, is a target gene and can be epigenetically
suppressed by AML1-ETO at the transcriptional level in t(8;21)
AML. Our findings also show that THAP10 is a bona fide target of
miR-383 that can be epigenetically activated by the AML1-ETO
recruiting co-activator p300. In this study, we demonstrated that
epigenetic suppression of THAP10 is the mechanistic link between
AML1-ETO fusion proteins and tyrosine kinase cascades. In addi-
tion, we showed that THAP10 is a nuclear protein that inhibits
myeloid proliferation and promotes differentiation both in vitro
and in vivo. Altogether, our results revealed an unexpected and
important epigenetic mini-circuit of AML1-ETO/THAP10/miR-383 in
t(8;21) AML, in which epigenetic suppression of THAP10 predicts a
poor clinical outcome and represents a novel therapeutic target.
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Introduction
t(8;21) acute myeloid leukaemia (AML) is a highly heterogeneous
disease from a biological and clinical standpoint (Hsiao et al,
2015). This remains a significant barrier to the development of
accurate clinical classification, risk stratification and targeted
therapy for this disease. Epigenetic control of gene expression
has been suggested to play a pivotal role in the biological beha-
viour of cells (Wouters & Delwel, 2016). Disruption of normal
DNA methylation distribution is a hallmark of cancer and has
critical roles in the initiation, progression and maintenance of
malignant phenotypes (Figueroa et al, 2010). Several tumour
suppressor genes [e.g. miR-193a (Li et al, 2013b) and miR-223
(Fazi et al, 2007a; Pulikkan et al, 2010)] have been shown to be
abnormally methylated in t(8;21) AML patients. Moreover, aber-
rant distribution of promoter DNA methylation occurring in
specific and distinct patterns was identified as a universal feature
in t(8;21) AML (Figueroa et al, 2010). However, the mechanisms
underlying these aberrant methyl cytosine patterns have not been
defined.
The thanatos-associated proteins (THAPs), a novel family of
cellular factors, are characterized by the presence of an evolution-
arily conserved protein motif (Cayrol et al, 2007). Overall, there
are 12 distinct human proteins that contain the THAP domain
(THAP 0–11; Zhu et al, 2009). Among them, THAP1 has been
identified as a nuclear protein associated with promyelocytic
leukaemia nuclear bodies (PML NBs; Cayrol et al, 2007). THAP7
has both histone-binding and putative DNA-binding motifs
(Macfarlan et al, 2005). THAP9 was shown to be an active DNA
transposase and still retains the catalytic activity to mobilize P
transposable elements across species (Majumdar et al, 2013). Most
recently, the mouse homolog of THAP11, Ronin, was identified as
an essential factor underlying embryogenesis and embryonic stem
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cell pluripotency (Dejosez et al, 2008). In contrast, Zhu et al
(2009) reported that THAP11 functions as a negative regulator of
cell growth in human hepatoma cells through transcriptional
repression of the proto-oncogene MYC. These studies, together
with data obtained in C. elegans, indicated that THAPs are zinc-
dependent, sequence-specific DNA-binding factors involved in cell
proliferation, apoptosis, the cell cycle, chromatin modification and
transcriptional regulation. However, the transcriptional regulatory
properties of most human THAPs and their roles in pathological
processes remain largely unknown.
Given the function of AML1-ETO as a transcriptional repres-
sor (DeKelver et al, 2013), we investigated whether AML1-ETO
was associated with aberrant epigenetic programming in t(8;21)
AML. Here, we report an unexpected and functional epigenetic
mini-circuit of AML1-ETO/THAP10/miR-383 in t(8;21) AML,
which might represent a novel therapeutic target as well as
a biomarker for predicting clinical outcome of patients with
AML.
Results
t(8;21) AML displays a distinct signature of aberrant
DNA methylation
First, we used a DNA methylation microarray for 450 k CpG sites to
profile genome-wide DNA methylation in AML blasts of patients
with or without t(8;21) (Appendix Table S1) and normal bone
marrow (NBM) CD34+ cells. The heatmap displayed a unique epige-
netic signature with global hypermethylation for t(8;21)+ AML,
which differed from either the t(8;21) AML or NBM samples
(Fig 1A). Unsupervised hierarchical clustering analysis revealed a
clear segregation of t(8;21)+ AML from t(8;21) AML blasts or
normal CD34+ cells (Appendix Fig S1), despite the heterogeneity of
AML blasts. It also showed that t(8;21)+ cases were further divided
into two sub-clusters (A and B) with distinguishable methylation
profiles (Appendix Fig S1). Interestingly, sub-cluster A contained
5 of 7 t(8;21)+ AML cases carrying Y chromosome deletion
(Appendix Table S1).
Analysis of the differentially methylated probes within 10 kb
from each gene transcriptional start site (TSS) identified a total of
888 differentially methylated probe sets (corresponding to 408
genes) in t(8;21)+ AML [Fig 1B, P < 0.001 and methylation log
ratio difference > 1.5 vs. t(8;21) AML]. In t(8;21)+ AML, func-
tional pathway analysis indicated that 57 and 17 hypermethylated
genes were grouped into the categories of cancer and AML,
respectively (Fig 1C). Among these genes (Appendix Table S2),
many are involved in tumour suppression [e.g. RB1 (Dyson,
2016)], apoptosis [e.g. BCL2L1 (Liu et al, 2015)], the cell cycle
[e.g. CCND1 (Mende et al, 2015), CCND2 (Khanjyan et al, 2013)]
or protein kinases [e.g. KIT (Wichmann et al, 2015), GSK3-b
(Orme et al, 2016)]. By combined with 408 differentially methy-
lated genes (Fig 1B), a systematic survey of the publicly available
databases (Gardini et al, 2008; Zhang et al, 2015) identified nine
transcriptional factor genes targeted by AML1-ETO that were dif-
ferentially hypermethylated in t(8;21) AML (Fig 1D). The same
approach was then used to analyse the data from TCGA methy-
lome (Ley et al, 2013), which identified 13 genes differentially
hypermethylated in t(8;21) AML (Fig EV1). Of note, 4 of these 13
genes matched those identified in our distinct signature of t(8;21)
AML (Fig 1D).
A strong hypermethylated signature of t(8;21) AML suggests a
therapeutic benefit from hypomethylating agents (e.g. 5-azacyti-
dine/5-Aza). Notably, 5-Aza treatment significantly increased apop-
tosis of AML1-ETO+ AML cells (Appendix Fig S2), compared to
their AML1-ETO counterparts. Together, these findings indicate a
distinct signature of aberrant DNA methylation in t(8;21) AML,
consistent with the hypothesis that AML1-ETO alters epigenetic
patterning to drive leukaemogenesis via deregulation of specific
complementary gene sets, which may be susceptible to hypomethy-
lating agents.
THAP10 is epigenetically suppressed in t(8;21) leukaemia cells
Differential methylated region (DMR) analysis was then performed
to explore the genes aberrantly methylated in t(8;21) AML. The top
10 genes with higher methylation levels in t(8;21)+ than t(8;21)
AML and NBM are shown in Appendix Table S3. Notably, both sets
of these top 10 genes and nine genes described above (Fig 1D)
included THAP10, while the other nine genes listed in
Appendix Table S3 were not found in the latter gene set. Moreover,
methylation levels of all 14 probes in the THAP10 promoter region
were higher in AML1-ETO+ than AML1-ETO blasts or NBM cells
(Appendix Fig S3), supporting THAP10 as a novel target gene epige-
netically regulated by AML1-ETO.
THAP10 mRNA levels were then determined to validate the
functional role of its promoter hypermethylation. Significantly,
core-binding factor [CBF, including t(8;21)] AML cell lines
displayed lower THAP10 mRNA levels than non-CBF cells
(Fig 2A). In a cohort of AML patients (Appendix Table S4),
THAP10 mRNA levels in AML blasts were lower than NBM cells,
while the lowest level of THAP10 was observed in t(8;21)+ AML
(Fig 2B). Virtually identical results were obtained from the analy-
sis of data from 200 AML samples in TCGA database (Fig EV2;
Ley et al, 2013). Interestingly, THAP10 mRNA levels in bone
marrow mononuclear cells of AML1-ETO+ AML patients who
achieved complete remission after induction chemotherapy were
relatively higher than the same patients at relapse (Fig 2C). In an
additional cohort of 124 AML/M2 patients (Appendix Table S5),
THAP10 mRNA levels were 0.9-fold lower in AML1-ETO+ than
AML1-ETO cases (Fig 2D).
As AML1-ETO and c-KIT gene abnormalities are associated with
poor outcome of patients with t(8;21) AML (Jiao et al, 2009; Qin
et al, 2014), we examined the relationships among expression of
THAP10, AML1-ETO and c-KIT in newly diagnosed t(8;21) AML
patients (Appendix Table S5). Notably, THAP10 mRNA level was
inversely correlated with those of AML1-ETO (Fig 2E) and c-KIT
(Fig 2F). Then, 76 patients with t(8;21) AML (Appendix Table S5)
were grouped into quartiles according to THAP10 levels and
divided into THAP10-high (n = 56) and THAP10-low patients
(n = 20; Appendix Fig S4). The results revealed that THAP10-high
patients had significantly longer overall (Fig 2G), event-free
(Fig 2H) or relapse-free (Fig 2I) survival than THAP10-low
patients. Together, these findings indicate that THAP10 gene
silencing is associated with unfavourable outcomes of t(8;21)
AML patients.
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AML1-ETO epigenetically suppresses THAP10 by binding to
AML1-binding sites
AML1-ETO retains the binding capacity to AML1-binding sites at
gene promoters, and it can also recruit additional transcriptional
cofactors, mostly corepressors (Li et al, 2013b). Notably, AML1-ETO
knock-down resulted in sharp increases (~15-fold compared to
controls) in THAP10 mRNA and protein levels in AML1-ETO+
SKNO-1 (Fig 3A). In contrast, ectopically expressing zinc-inducible
HA-tagged AML1-ETO significantly reduced THAP10 levels in U937
cells (Fig EV3A). However, despite the significant difference in
mRNA levels of THAP10, there was only a moderate difference in
THAP10 protein levels between AML1-ETO HL60 and AML1-ETO+
Kasumi-1 cells (Fig 3A). This inconsistency suggests that other
mechanism(s) may also contribute to the protein level of THAP10.
Nevertheless, these results indicate that AML1-ETO inhibits THAP10
expression.
A bioinformatics search (http://www.cbrc.jp/research/db/
TFSEARCH.html) at the 50 end of the predicted “core promoter”
sequence revealed seven putative AML1-binding sites surrounded by
CpG islands in the THAP10 upstream region (2,000 nt to +1 nt rela-
tive to TSS; Fig 3B, upper panel). Accordingly, luciferase reporters
containing a series of wild-type (P1–P8) or mutated (P4-M to P6-M)
sequences of the THAP10 promoter region (Fig 3B, lower panels)
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Figure 1. AML1-ETO+ AML displays a unique genome-wide methylation profile compared to AML1-ETO AML and normal bone marrow CD34+ cells.
A Overview of two-way (genes against samples) hierarchical clustering of AML1-ETO+ (n = 12), AML1-ETO (n = 28) M2 AML blasts and normal bone marrow cells
(NBM, n = 2) using the genes that vary the most among samples. Representative heatmap is shown to identify the aberrant DNA methylation signatures of specific
genes in AML, compared to normal CD34+ haematopoietic cells obtained from healthy donors. In this heatmap, each column represents one gene, and each row
represents one AML patient or healthy donor. Red bar, t(8;21) M2 AML. Blue bar, t(8;21)+ AML. Green bar, normal bone marrow (NBM).
B Volcano plot illustrating the methylation difference between AML1-ETO+ (n = 12) and AML1-ETO (n = 28) AML samples, with the corresponding moderated t-test
P-values. Red, probe sets that were significantly hypermethylated (P < 0.001, methylation difference > 1.5); green, probe sets that were significantly hypomethylated
(P < 0.001, methylation difference < 1.5); blue, probe sets that did not have an absolute methylation difference > 1.5.
C Functional enrichment analysis of differential DNA methylation genes (DMGs), based on the pathway enrichment analysis of hypergeometric distribution.
D Venn diagrams for systematic survey of the publicly available database, by combining with 408 differentially methylated genes identified in the present study (see
panel B), to identify the 9-gene set in t(8;21) AML.
Data information: All experiments were performed in triplicate.
Source data are available online for this figure.
ª 2017 The Authors EMBO Molecular Medicine
Yonghui Li et al AML1-ETO/THAP10/miR-383 in t(8;21) AML EMBO Molecular Medicine
3
Published online: May 24, 2017 
R
el
at
iv
e 
TH
A
P
10
 E
xp
re
ss
io
n
0
20
40
60
80
100
120
t(8;21)
0
50
100
150
200
250
R
el
at
iv
e 
TH
A
P
10
 E
xp
re
ss
io
n
BM M0 M1 M2 M3 M4 M4eo M5 M6 M7
t(8;21)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 2
1 25 26 27 2822 23 24
0
100
200
300
Diagnosis
Remission
Relapse
R
el
at
iv
e 
TH
A
P
10
 E
xp
re
ss
io
n
P1       P2      P3      P4   
N=76 N=48
150
120
90
60
30
0
R
el
at
iv
e 
TH
A
P
10
 E
xp
re
ss
io
n
AE+ AE-
P=0.001
R
el
at
iv
e 
E
xp
re
ss
io
n 
of
 A
E
 
Relative Expression of THAP10 
200
150
100
50
0
P=0.000, R=-0.288
806040200
0
200
400
600
800
1000
1200
806040200
Relative Expression of THAP10
R
el
at
iv
e 
E
xp
re
ss
io
n 
of
 c
-K
IT
P=0.000, R=-0.512
A C
B D
E F
G H I
Figure 2. THAP10 is down-regulated in t(8;21) AML and correlates with adverse clinical outcome.
A, B Relative qRT–PCR quantification of THAP10 mRNA levels in the indicated leukaemia cell lines (A) and mononuclear cells (MNC) isolated from leukaemia patients (B)
(n = 28).
C Sequential analyses of THAP10 mRNA levels in mononuclear cells isolated from bone marrow samples of four individual leukaemia patients at different stages of
disease, including newly diagnosed, remission and relapse.
D Comparison of THAP10 mRNA levels in two categories of AML M2 subtype patients (total n = 124): AML1-ETO+ (n = 76) and AML1-ETO (n = 48) t(8;21) AML,
P = 0.001. Data are represented as a boxplot, which shows the median value of mRNA levels (line in the middle of the box), the first and the third quartiles (lower
and upper limits of each box, respectively). Wiskers display the highest and lowest data values.
E, F Correlations in gene expression between THAP10 and AML1-ETO (R = 0.288, P = 0.000, E) or c-KIT (R = 0.512, P = 0.000, F), the two-sided paired Pearson test
was used for the significance of association.
G–I Correlations of THAP10 expression (high, n = 56; low, n = 20) with overall survival (P = 0.001, G), event-free survival (P = 0.046, H) and relapse-free survival
(P = 0.039, I). The cut-off value (dash line) is 2 × 101 of THAP10 level, by which high vs. low THAP10 mRNA expression is defined, the log-rank test was used for the
survival analysis.
Data information: Data are expressed as the mean  SEM.
Source data are available online for this figure.
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Figure 3. AML1-ETO epigenetically suppresses THAP10 via direct binding to its promoter region.
A Upper panel: Relative quantification of THAP10 mRNA levels in the indicated leukaemia cell lines. The results represent the mean of three independent
evaluations  SD (*P = 0.001, #P = 0.0007, Student’s t-test was used for the comparisons). Middle and lower panels: mRNA and protein levels of THAP10 and AML1-
ETO, respectively.
B Upper panel: Schematic diagrams of the AML1-binding sites and the CpG islands along the THAP10 genes. Numbers indicate the nucleotides relative to pre-THAP10
(1 nt). Vertical arrowheads indicate the AML1-binding sites; vertical lines indicate CpG dinucleotides; horizontal bar illustrates the regions analysed by bisulphite
sequencing. Lower panels: A series of constructs containing different AML1-binding sites and their mutants.
C Luciferase reporter activities of human 293T cells transiently co-transfected for 48 h with luciferase reporters containing the wild-type sequence of the THAP10
promoter or its mutant counterparts, together with increasing amounts of pcDNA3.0 vectors containing AML1-ETO or mock cDNA (293T-Mock). Triplicate values are
defined as mean ± SD.
D Chromatin immunoprecipitation (ChIP) using the indicated antibodies or IgG, after which qRT–PCR was performed to evaluate the specificity of protein binding.
Triplicate values are defined as mean ± SD.
E Genomic bisulphite sequencing to detect the methylation status of the DNA sequences surrounding the AML1-binding site (280 nt) in the pre-THAP10 gene upstream
region in CD34+ haematopoietic progenitors isolated from peripheral blood (PB) of healthy donors, the indicated leukaemia cell lines and primary leukaemic blasts.
Each row of circles represents the sequence of an individual clone. Solid and empty circles represent methylated and unmethylated CpG dinucleotides, respectively.
Data information: All experiments were performed in triplicate.
Source data are available online for this figure.
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were designed, and 293T cells were co-transfected with each reporter
together with increasing amounts of AML1-ETO or empty vectors.
Notably, ectopic AML1-ETO expression resulted in a dose-dependent
decrease in luciferase activity of THAP10-P1-6 or THAP10-P4-M and
THAP10-P5-M but not THAP10-P6-M and THAP10-P8, which lack an
AML1-binding site (Figs 3C and EV3B), suggesting that AML1-ETO
binds to the proximal AML1-binding sites of the THAP10 promoter
to suppress THAP10. Moreover, ChIP assays revealed that shRNA
knock-down of AML1-ETO in SKNO-1 cells resulted in a sharp
decrease in binding of AML1-ETO, HDAC1, DNMT1, DNMT3a and
DNMT3b to the region around the AML1-binding sites of the THAP10
promoter compared to control SKNO-1 cells (Fig 3D). In contrast,
ectopic overexpression of AML1-ETO in U937 cells led to a marked
increase in binding of these proteins compared to control U937 cells
(Fig 3D). Similar results were obtained in primary AML1-ETO+ vs.
AML1-ETO AML blasts (Fig EV3C).
Further, bisulphite sequencing assays revealed a higher
frequency of methylated CpG dinucleotides encompassing THAP10
in AML1-ETO+ SKNO-1 (75%) and U937-A/E cells (90%) than
U937 (54%) and HL-60 (32%) or normal CD34+ cells (5%)
(Fig 3E). In contrast, AML1-ETO knock-down in SKNO-1 cells
dramatically diminished THAP10 CpG methylation (Fig 3E). The
frequency of methylated CpG dinucleotides encompassing endoge-
nous THAP10 was higher in AML1-ETO+ (85%) than AML1-ETO
(3.8%) AML blasts (Fig 3E). Interestingly, while treatment with
5-Aza increased THAP10 expression by ~4.0-fold in AML1-ETO+
cells displaying strong hypermethylation of THAP10 (Fig 3E), co-
treatment with 5-Aza and the HDAC inhibitor TSA further increased
its expression (Fig EV3D). These findings are likely due to increas-
ing acetylation (activation) of the THAP10 promoter via inhibition
of the co-repressor HDAC1, which was recruited to the AML1-
binding sites of THAP10 (Fig 3D) by HDAC inhibitors (e.g. TSA).
Treatment with another hypomethylating agent (decitabine) +/
the clinically relevant HDAC inhibitor chidamide also increased
THAP10 expression ex vivo in primary blasts (Fig EV3E) as well as
in vivo in patients enrolled in an ongoing clinical trial
(NCT02886559; Fig EV3F). Together, these findings suggest that
AML1-ETO in an abnormal chromatin remodelling complex with
other cofactors (e.g. DNMTs) mediates hypermethylation of CpG
islands around AML1-binding sites on the THAP10 promoter, while
probably increasing histone deacetylation (e.g. by HDAC1) on the
THAP10 promoter as well, which might represent a novel mechanism
responsible for suppression of THAP10 expression in t(8;21) AML.
THAP10 is a bona fide target of miR-383 that is up-regulated in
AML1-ETO+ leukaemia cells
In addition to the mechanism described above in which AML1-ETO
directly suppresses the THAP10 gene by methylating its promoter,
we then examined whether other mechanism(s) were also involved
in suppression of THAP10 expression in AML-ETO+ AML. Micro-
RNAs (miRNAs) play an important role in the lineage differentiation
of haematopoietic cells by regulating expression of oncogenes or
tumour suppressors (Vian et al, 2014). Deregulation of miRNA
expression has been shown to be involved in multistep carcinogen-
esis and has rapidly emerged as a novel therapeutic target (Li et al,
2013b; Dorrance et al, 2015; Tarighat et al, 2016). Computational
analysis for miRNA target prediction using the TargetScan
algorithm (http://www.targetscan.org) revealed THAP10 as a puta-
tive target of miR-383 (Fig 4A). To validate the functional role of
miR-383 in regulation of THAP10 expression, 293T cells were co-
transfected with THAP10 30-UTR luciferase reporters and pre-miR-
383. As shown in Fig EV4A, expression of miR-383 resulted in a
~50% reduction in luciferase activity of wild-type THAP10 30-UTR
but not in miR-383-binding site-mutated THAP10 30-UTR (Fig 4A).
Furthermore, administration of synthetic miR-383 also reduced
endogenous THAP10 expression at the mRNA level in HL-60 and
NB4 cells (Fig EV4B) and the protein level (Fig 4B). Taken together,
these results indicate that THAP10 is a bona fide target of miR-383.
qRT–PCR analysis revealed higher miR-383 levels in t(8;21)+
than t(8;21) AML cell lines (Fig 4C) and blasts (Fig 4D) in a cohort
of AML patients (Appendix Table S4). Interestingly, miR-383 expres-
sion was decreased in bone marrow mononuclear cells of AML1-
ETO+ patients who achieved complete remission following induc-
tion chemotherapy, compared to the same patients at relapse
(Fig 4E). These findings were further validated by results showing
that miR-383 levels were twofold higher in AML1-ETO+ than AML1-
ETO AML blasts (Fig 4F) in an additional cohort of 124 AML cases
(Appendix Table S5).
Furthermore, AML1-ETO knock-down decreased miR-383 expres-
sion by ~sevenfold in AML1-ETO+ cells, compared to controls
(Fig EV4C). In contrast, ectopic expression of AML1-ETO in U937
cells increased miR-383 levels by 2.4-fold (Fig EV4D). Consistently,
qRT–PCR analysis revealed an inverse correlation between miR-383
and THAP10 expression (Fig 4G), but a positive correlation between
miR-383 and AML1-ETO expression (Fig 4H), in a cohort of newly
diagnosed t(8;21) AML patients (Appendix Table S5). Together,
these findings suggest that miR-383 expression correlates negatively
with THAP10 but positively with AML1-ETO in t(8;21) AML.
AML1-ETO transcriptionally induces expression of miR-383
The NHR1 domain of AML1-ETO provides a docking site for p300
binding, allowing it to co-localize at the regulatory regions of many
AML1-ETO target genes (Wang et al, 2011). A bioinformatics search
(http://www.cbrc.jp/research/db/TFSEARCH.html) of the miR-383
at the 50 end of the predicted “core promoter” sequence revealed
three putative AML1-binding sites and one p300-binding site
(Fig 5A, upper panel). Accordingly, luciferase reporters containing a
series of wild-type (MIR-P1 to MIR-P4) or mutated (MIR-P1-M to
MIR-P3-M) sequences of the miR-383 promoter region (Fig 5A,
lower panels) were designed, and 293T cells were co-transfected
with each reporter together with increasing amounts of AML1-ETO
or empty vectors. Ectopic AML1-ETO expression resulted in a dose-
dependent increase in luciferase activity of MIR-P1, MIR-P1-M and
MIR-P2, but not MIR-P2-M, MIR-P3 and MIR-P4 (Fig 5B), suggesting
that the AML1-binding sites in the promoter region (676 nt rela-
tive to +1 nt) of miR-383, which is close to the p300-binding site
(669 nt relative to +1), might be involved in AML1-ETO-mediated
expression of miR-383.
ChIP analysis revealed the presence of AML1-ETO and p300,
rather than HDAC1, DNMT1, DNMT3a and DNMT3b, in the miR-
383 promoter region surrounding the AML1-binding sites (Fig 5C).
Furthermore, ChIP analysis using antibody against acetylated
histone H3 showed that acetylation levels within the miR-383
promoter region around the AML1-ETO- and p300-binding sites
EMBO Molecular Medicine ª 2017 The Authors
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Figure 4. miR-383 negatively correlates with THAP10 levels but positively correlates with AML1-ETO.
A The sequences indicating the putative interaction site between the miR-383 seed region (nucleotides 2–8) and the 30-UTRs of THAP10 wild-type (WT) or mutated
derivatives.
B Western blot analysis monitoring the effect of synthetic miR-383 on THAP10 protein levels.
C, D Relative qRT–PCR quantification of THAP10 mRNA levels in the indicated leukaemia cell lines (C) and mononuclear cells (MNC) isolated from leukaemia patients (D)
(n = 28). Triplicate values are defined as mean  SD.
E Sequential analyses of miR-383 levels in mononuclear cells isolated from bone marrow samples of four individual leukaemia patients at the newly diagnosed,
remission and relapse stages, respectively. Triplicate values are defined as mean  SD.
F Relative qRT–PCR quantification of THAP10 mRNA levels in two groups of AML M2 subtype patients (total n = 124): AML1-ETO+ and AML1-ETO t(8;21) AML
(P = 0.001). Data are represented as a boxplot, which shows the median value of mRNA levels (line in the middle of the box), the first and third quartiles (lower
and upper limits of each box, respectively). Whiskers display the highest and lowest data values.
G, H Correlation of miR-383 expression with THAP10 (R = 0.689, P = 0.001, G) or AML1-ETO levels (R = 0.346, P = 0.002, H). Two-sided paired Pearson test was used
for the significance of association.
Data information: All experiments were performed in triplicate.
Source data are available online for this figure.
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A Upper panel: Schematic diagrams of the AML1- and p300-binding sites and the CpG islands along the pre-miR-383 genes. Numbers indicate the nucleotides relative
to pre-miR-383 (+1 nt). Vertical arrowheads indicate AML1 (dark) and p300 (grey) binding sites; horizontal arrows indicate the location of the primers used for the
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C ChIP using the indicated antibodies or IgG, after which qRT–PCR was performed to evaluate the specificity of protein binding. Triplicate values are defined as mean 
SD.
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Data information: All experiments were performed in triplicate.
Source data are available online for this figure.
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were higher in AML1-ETO+ than AML1-ETO cells (Fig 5D). Given
the role of the interaction between AML1-ETO and p300 in regula-
tion of histone acetylation (Wang et al, 2011), the chemical p300
inhibitor C646 was then used to determine the function of p300 in
acetylation of the miR-383 promoter region around the AML1-ETO-
and p300-binding sites. Indeed, C646 treatment substantially
decreased acetylation of histone H3 (lysine 9/14) as well as AML1-
ETO in Kasumi-1 cells (Fig 5E), while it increased THAP10 levels
(Fig 5F). Together, these findings indicate that AML-ETO recruits
p300 to the AML1-binding sites in the pre-miR-383 regulatory region
and therefore transcriptionally activates miR-383 expression, which
in turn suppresses THAP10 expression, suggesting an alternative
indirect mechanism for AML-ETO to negatively regulate THAP10
expression in t(8;21) AML.
THAP10 is a nuclear protein that inhibits proliferation but
promotes differentiation of t(8;21) AML cells
In Drosophila, several THAP proteins are putative transcription
factors (Sabogal et al, 2010), indicating that human THAP10 may
also regulate transcription. Thus, we first examined whether
THAP10 was localized in the nucleus, where transcriptional factors
function to regulate gene expression. To this end, NIH3T3 cells were
transfected with EGFP-fused THAP10 cDNA to monitor subcellular
localization of THAP10 protein. In contrast to GFP, which was
distributed throughout the cell, GFP-THAP10 was found only in the
nucleus (Fig 6A). Western blot analysis further validated nuclear
localization of endogenous THAP10 protein in Kasumi-1 cells trans-
duced with lentivirus vector expressing THAP10 (Fig EV4E). More-
over, immunofluorescence staining for THAP10 also revealed that
the endogenous THAP10 protein predominantly localizes in the
nuclei of HL-60 cells and, to a lesser extent, in Kasumi-1 cells and
t(8;21) AML blasts (Fig EV4F). Together, these findings suggest that
the THAP10 gene encodes a nuclear protein.
To examine the functional role of THAP10 in leukaemogenesis of
t(8;21) AML, microarray analysis of global gene expression was
performed to identify the genes and pathways that correlate with
THAP10 (Fig 6B) in Kasumi-1 cells stably expressing THAP10
(Fig EV4G). Strikingly, classification based on the gene ontology
(GO) annotation showed that in THAP10-expressing Kasumi-1 cells,
the significantly down-regulated genes were related to either recep-
tor tyrosine kinase signalling pathways or cell differentiation
(Appendix Table S6), suggesting the selectivity of THAP10 in inhibi-
tion of gene expression. These results were further validated by
qPCR using specific primers for 15 distinct genes that were selected
either from the transmembrane receptor protein tyrosine kinase
signalling pathway or from the haematopoietic progenitor cell dif-
ferentiation pathway. All these 15 genes were down-regulated by at
least twofold in THAP10-expressing Kasumi-1 cells compared to
controls (Fig 6C). For detection of the total tyrosine phosphoryla-
tion, Western blot analyses showed a diminution of approximately
50% in p-Tyr levels in THAP10-expressing Kasumi-1 cells compared
with mock-transduced cells (Appendix Fig S5). Thus, these findings
suggest that THAP10 inhibits cell proliferation by suppressing the
genes associated with the enzyme-linked receptor signalling cascade,
which may promote cell differentiation.
The role of THAP10 in myeloid cell proliferation/differentiation
was then examined. Ectopic THAP10 expression significantly
reduced proliferation of Kasumi-1 cells (Fig 6D). Conversely, shRNA
knock-down of THAP10 (Fig EV5A) markedly promoted cell prolif-
eration (Fig 6E) in HL-60 cells that displayed a relatively high basal
level of THAP10 (Fig 3A). Moreover, ectopic THAP10 expression
led to significant reductions in both number (~45%) and size of
CFUs in Kasumi-1 cells (Fig 6F), while THAP10 shRNA knock-down
increased the number (~75%) and size of CFUs in HL-60 cells
(Fig 6G). Finally, ectopic THAP10 expression also induced
myelomonocytic differentiation of SKNO-1 cells, as shown by
morphological changes indicating maturation towards granulocytes
(e.g. chromatin condensation, decreased nuclear/cytoplasmic ratio
and appearance of primary granules; Fig 6H), as well as an increase
(1–17.5%) in CD11b+ differentiated cells (Fig 6I). Taken together,
these findings indicated that the nuclear protein THAP10 inhibits
proliferation but promotes differentiation of t(8;21) AML cells.
The AML1-ETO/miR-383/THAP10 axis plays a functional role in
leukaemogenesis of t(8;21) AML in vivo
Finally, the anti-leukaemic function of THAP10 was examined
in vivo. Kasumi-1 cells ectopically expressing THAP10 were
engrafted subcutaneously in the flank of immunocompromised
BALB/c nude mice. Tumours formed from THAP10-expressing cells
were significantly smaller than the empty-vector control
(P = 0.0016) or parental counterparts (P = 0.0015) at day 28 post-
cell inoculation (Fig 7A–C), with an average tumour weight of
1.80 g for THAP10-expressing cells vs. 5.25 g for empty-vector
controls (P = 0.0009, Fig 7D). Ectopic THAP10 expression markedly
increased THAP10 mRNA (Fig EV5B, upper panel) and protein
levels (Fig EV5B, lower panels) in xenografts.
Similar experiments were performed to examine the effect of miR-
383 on tumour growth. t(8;21)+ SKNO-1 cells were inoculated
subcutaneously into the flank of BALB/c nude mice as described
above. When tumour size reached 50 mm3, synthetic anti-miR-383
or scramble oligonucleotides were intratumourally injected as illus-
trated in Fig EV5C. On day 14 post-first treatment, treatment with
anti-miR-383 significantly reduced tumour size (P = 0.0025 vs.
scramble oligonucleotide; P = 0.0018 vs. untreated control;
Fig 7E–G), with an average tumour weight of 2.10 g for the anti-
miR-383 vs. 5.15 g for the scramble oligonucleotide groups
(P = 0.001, Fig 7H). Finally, anti-miR-383 treatment markedly
diminished miR-383 expression (Fig EV5D, upper panel), while it
increased THAP10 protein levels (Fig EV5D, lower panels) in tumour
tissue. To determine whether the in vivo activity of anti-miR-383 is
selective against AML-ETO+ AML, t(8;21) HL-60 cells were inocu-
lated subcutaneously and intratumourally injected with anti-miR-383
or scramble oligonucleotides as described above. As shown in
Fig EV5E and F, there was no significant difference in either tumour
size or weight between anti-miR-383 and scramble oligonucleotide
(4.85 g vs. 4.63 g, P = 0.700). Collectively, these findings strongly
indicate that THAP10 expression, which is negatively regulated by
miR-383, functionally inhibits leukaemogenesis of t(8;21) AML.
Discussion
Aberrant DNA methylation and/or deacetylation are major factors
in epigenetic gene silencing. Indeed, disruption of DNA methylation
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Figure 6. THAP10 localizes in the nuclei and inhibits proliferation but promotes differentiation of t(8;21) AML cells.
A Nuclear localization of THAP10 in NIH3T3 cells. Scale bar, 10 lm.
B Representative heatmap of the aberrant gene profile of Kasumi-1 cells transduced with or without THAP10 using lentivirus. Each column indicates a gene, and 1–3
indicate three independent pools of cells.
C Fold changes in the mRNA levels for 15 selected genes measured by RT–PCR.
D Growth curve of Kasumi-1 cells transduced with THAP10 (Lenti-T10) or lentiviral empty vector (Vector).
E Growth curve of HL-60 cells transfected with synthetic si-THAP10 (si-T10) or scramble (siLuc) sequences.
F, G Analysis of CFUs in Kasumi-1 (F, *P = 0.026) and HL-60 cells (G, *P = 0.018) using a methylcellulose culture system. Scale bar, 1 mm. Two-sided Student’s t-test
was used for the comparisons.
H Morphological analysis of Kasumi-1 cells at 4 days after transduction with empty vector or Lenti-THAP10 (T10). Scale bar, 10 lm.
I Flow cytometric analysis of CD11b expression in Kasumi-1 cells at 144 h after transduction with Lenti-THAP10 (T10) or control vector (Vec). Wild-type Kasumi-1
cells as control (Con) (*P = 0.005). Two-sided Student’s t-test was used for the comparisons.
Data information: All experiments were performed in triplicate. In (C–G and I), the results represent the mean of 3 independent evaluations  SD.
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F Tumour growth in mice engrafted with SKNO-1 cells ectopically expressing anti-miR-383.
G Tumour volumes measured at the indicated days during the experiment (wild type, n = 5; scramble, n = 6; synthetic anti-miR-383, n = 6). Values are defined as
mean  SD.
H The mean  SD of tumour weight at the end of the experiment (WT, wild type, n = 5; Scr, scramble, n = 6; Anti-miR, anti-miR-383, n = 6; *P = 0.009). Two-sided
Student’s t-test was used for the comparisons.
I A schematic model for the epigenetic suppression of THAP10 by AML1-ETO directly or indirectly via miR-383 and the interplays between AML1-ETO and the co-
repressors DNMTs and HDACs or the co-activator p300. Epigenetic suppression of THAP10 represents a mechanistic link between AML1-ETO fusion protein and the
tyrosine kinase cascades by targeting their downstream genes, which mediate inhibition of myeloid proliferation and promotion of cell differentiation in t(8;21) AML.
Data information: All experiments were performed in triplicate. In (D and H), data are expressed as the mean  SD.
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patterns is frequently present in aberrant development and leukae-
mogenesis (Oakes et al, 2016). The present study unveiled a novel
epigenetic mini-circuitry of AML1-ETO/THAP10/miR-383 in t(8;21)
AML, which plays a functional role in leukaemogenesis of this
poor-prognostic AML subtype. The oncogenic transcription factor
AML1-ETO, a fusion protein generated by t(8;21) translocation, can
recruit DNMTs to and subsequently hypermethylate the promoters
of its target genes (Fazi et al, 2007a; Li et al, 2013b). In this study,
we showed that t(8;21) AML blasts displayed a specific methylation
signature, distinct from those of t(8;21) AML and normal CD34+
cells, which was functionally associated with AML1-ETO.
We identified THAP10 as a target gene of AML1-ETO. The onco-
genic effect of AML1-ETO is primarily linked to its ability to form
oligomeric complexes with an increased affinity for HDACs and
DNMTs, which render AML1-ETO a potent transcriptional repressor
of AML1-target genes. In this context, it has been reported that
RARb2, a retinoic acid (RA)-regulated tumour suppressor gene, is
silenced by aberrant DNA methylation in a variety of human malig-
nancies, including t(8;21) AML (Fazi et al, 2007b). Here, we showed
that AML1-ETO directly bound to and hypermethylated the promoter
region of THAP10, resulting in epigenetic suppression of this gene.
THAP10 and LRRC49 (leucine rich repeat containing 49), both
located on chromosome 15q23 in close proximity, were simultane-
ously suppressed due to hypermethylation of the bidirectional
promoter region in breast cancer (De Souza Santos et al, 2008). The
present findings indicate that THAP10 acts as a tumour suppressor in
t(8;21) AML, suggesting that AML1-ETO promotes leukaemogenesis
via epigenetic suppression of THAP10. Therefore, THAP10 expres-
sion may predict a favourable clinical outcome of patients with
t(8;21) AML. The relevance of this finding in AMLs is underlined by
the fact that aberrant heterochromatic gene silencing can represent
an alternative mechanism to gene mutation or deletion for the tran-
scriptional repression of tumour suppressor genes (Baylin & Ohm,
2006; Mack et al, 2015). However, we could not rule out the possibil-
ity that other AML1-ETO-targeted genes (e.g. those depicted in
Fig 1D) might also be involved in leukaemogenesis driven by this
oncogenic fusion protein.
In addition to direct epigenetic suppression of the THAP10 gene
via methylation of its promoter by AML1-ETO, a question then
arose whether this represents the sole mechanism for AML1-ETO
to inhibit THAP10 expression or whether other mechanism(s)
could also be involved in suppression of THAP10 expression in
AML-ETO+ AML. We further demonstrated that THAP10 is also a
bona fide target of miR-383, a miRNA associated with several
types of solid tumour (Lian et al, 2010; He et al, 2013; Li et al,
2013a; Riaz et al, 2013; Zhao et al, 2014). Interestingly, AML1-
ETO bound to the promoter of miR-383 and activated its expres-
sion, while miR-383 in turn suppressed expression of THAP10.
Therefore, these findings indicate that AML1-ETO inhibits expres-
sion of the tumour suppressor THAP10 directly via epigenetic
suppression of the THAP10 promoter and indirectly through tran-
scriptional activation of miR-383 in t(8;21) AML (Fig 7I). This
hypothesis is supported by findings indicating that the differentia-
tion response to increased THAP10 can be restored in t(8;21) cell
lines and blasts by (i) changing the methylation status at regula-
tory sites on the AML1-ETO target gene THAP10 by AML1-ETO
knock-down via RNAi or pharmacologic treatment with the
demethylating agent 5-azacytidine and (ii) impairing the
interaction between AML1-ETO and the transcriptional co-activator
p300 using the chemical inhibitor C646 or treatment with
synthetic anti-miR-383.
Recent evidence suggests that alterations in transcription
factors and tyrosine kinases represent two classes of the most
frequently detected genetic events in human leukaemias.
However, whether a causal relationship exists between the two
genetic events remains largely unknown. The large-scale gene
expression profiling in the present study showed that THAP10 acts
as a transcriptional repressor to selectively modulate the enzyme-
linked receptor tyrosine kinase signalling cascade and cell dif-
ferentiation in t(8;21) AML. Thus, epigenetic suppression of
THAP10 may link to both the first hit (e.g. AML1-ETO) and the
second hit (e.g. tyrosine kinase signalling cascade). Thus, we
hypothesize that “loss of function” of the transcriptional repressor
THAP10 may result in activation of a key tyrosine kinase path-
way, which then promotes cell proliferation but blocks cell dif-
ferentiation of myeloid progenitors. Indeed, ectopic expression of
THAP10 resulted in a clear increase in differentiated cells with
specific morphologic features and the CD11b marker. However,
the mechanism(s) underlying THAP10-mediated cell differentiation
remains to be defined. Interestingly, there were significant inverse
correlations between THAP10 and AML1-ETO or tyrosine kinase
C-KIT mRNA levels, implying that high levels of THAP10 may
indicate a good clinical outcome of patients with t(8;21) AML.
Therefore, these findings strongly suggest that THAP10 is a
tumour suppressor candidate as well as a potential biomarker for
leukaemogenesis of t(8;21) AML.
In summary, this study identified AML1-ETO/THAP10/miR-383
as a novel epigenetic mini-circuitry in t(8;21) AML, thereby provid-
ing new insight into the mechanism of action of AML1-ETO in driv-
ing leukaemogenesis. These findings also suggest that THAP10 and
miR-383 are novel biomarkers and therapeutic targets in this AML
subtype. Furthermore, this study presents new evidence for a func-
tional link between the AML1-ETO protein, cell proliferation and dif-
ferentiation, and the abnormal tyrosine kinase signalling pathway in
human t(8;21) AML. Our study also provided new insight into the
molecular processes required for myeloid differentiation and identi-
fied possible new targets for the development of novel therapeutic
approaches to leukaemia. Future studies should aim to (i) determine
the roles of other human THAP proteins in cell proliferation, (ii)
define the composition of the endogenous THAP10 protein
complexes and (iii) characterize the potential links between
THAP10 and its targets in regulating specific promoters involved in
tyrosine kinase signalling pathways.
Materials and Methods
Cell lines and patient samples
HL-60, NB4, ME-1, Molt-4, THP-1, MM6, K5652, MV4-11, Jurkat,
RAJI, U937, U937-A/E-HA, Kasumi-1, SKNO-1, SKNO-1-siA/E and
KG1 cell lines were maintained in RPMI 1640 medium supple-
mented with 50 lg/ml streptomycin, 50 IU penicillin and 10% FCS.
SKNO-1 cells were infected with the pRRLcPPT.hPGK, the lentiviral
vector encoding the previously described siAGF1 oligonucleotides
(Appendix Table S7) against the AML1-ETO mRNA fusion site
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(siA/E-RNAs) for silencing of AML1-ETO (Fazi et al, 2007a;
Martinez Soria et al, 2009; Li et al, 2013b). The U937-A/E-HA clone
was obtained by transfection via electroporation of U937 wild-type
(WT) cells with an HA-tagged AML1-ETO cDNA subcloned into a
vector carrying the Zn2+-inducible mouse MT-1 promoter, as previ-
ously reported (Fazi et al, 2007b). Human embryonic kidney (HEK)
293T cells were cultured in DMEM medium supplemented with
50 lg/ml streptomycin, 50 IU penicillin and 10% FCS. Treatments
with 5-azacytidine (2.5 lM, Sigma-Aldrich), decitabine (2.5 lM,
Xi0an Janssen Pharmaceutical Ltd.) and chidamide (3.0 lM, Shen-
zhen Chipscreen Biosciences Ltd.) were performed for 40 h.
This study was approved by the Human Subject Ethics Commit-
tee in Chinese PLA General Hospital and conducted in accordance
with the Declaration of Helsinki. Informed consent was obtained
from each subject. Mononuclear cells from bone marrow samples of
newly diagnosed, untreated AML patients and healthy donors were
isolated using Ficoll-Hypaque (Sigma-Aldrich, St Louis, MO) gradi-
ent centrifugation. Patient characteristics are summarized in
Appendix Tables S1, S4 and S5.
RNA and protein extraction and analysis
Total RNA was extracted from cells using the TriPure isolation
system (Roche). The relative quantity of THAP10 mRNA was
measured using 200 ng of total RNA by qRT–PCR with qRT–PCR
Detection Kit (Ambion, Applied Biosystems, Milan) and the ABI
PRISM 7500 Sequence Detection System (Applied Biosystems). Gene
expression was determined by the comparative CT method using
ABL levels for normalization as recommended in the manufacturer’s
instructions. Whole cell proteins were extracted using RIPA lysis
buffer. Nuclear and cytoplasmic proteins were separated using the
NE-PER Nuclear and Cytoplasmic Extraction Kit (Thermo Scientific,
Waltham, MA) as per the manufacturer’s instructions.
Immunofluorescence and confocal microscopy
Analysis for nuclear localization of endogenous THAP10 was
performed in transfected cells [NIH3T3 cells transfected with pEGFP
or pTHAP10-EGFP; cells were grown on poly-D-lysine-coated cover
slips (BD Biosciences, San Jose, CA, USA) 24 h after transfection] or
Kasumi-1, HL-60 and t(8;21) AML blasts. Briefly, cells were fixed for
20 min with 4% cold paraformaldehyde and then permeabilized for
5 min with 0.05% Triton X-100. Cells were incubated with 10 ll of
Hoechst33342 (100 mg/l, Thermo Fisher Scientific) for 15 min for
transfected cells. For Kasumi-1, HL-60 and t(8;21) AML blasts,
permeabilized cells were then blocked with PBS-BSA (PBS with 1%
bovine serum albumin) and incubated with THAP10 primary anti-
bodies (2 lg/ml, NBP1-86226, Novus Biologicals, USA) overnight at
4. Cells were then washed three times in PBA-BSA and incubated
in the dark for 1 h with Alexa Fluor 488-conjugated secondary anti-
bodies (1/500, #4412, Cell Signalling Technology, USA) diluted in
PBA-BSA. After three PBS washes, nuclei were counterstained with
DAPI (0.2 lg/ml, #4083, Cell Signalling Technology, USA). Follow-
ing extensive washing in PBS, samples were air-dried and mounted
in Rubber Cement (Union Rubber, Inc., Trenton, NJ, USA).
Immunofluorescence images were captured using confocal micro-
scopy (LSM 880, ZEISS, Germany). Green, GFP-THAP10 or endoge-
nous THAP10; blue, nucleus.
DNA methylation microarray for 450 k CpG sites
Microarray-based DNA methylation analysis with 450 k arrays was
used to profile genome-wide DNA methylation in primary cells,
using an Infinium Human Methylation 450 BeadChip with an Infi-
nium HD methylation assay kit and HiScanSQ (Illumina), which
assesses the methylation status at more than 485,000 individual
CpG sites, encompassing 99% of reference sequence genes and 96%
of CpG islands.
Total DNA was extracted using Wizard a genomic DNA purifica-
tion kit (Promega Corp., WI, USA). DNA quality was determined
with a Nano Drop 2000c spectrophotometer (Thermo Fisher Scien-
tific Inc., Wilmington, DE), and 1 lg of DNA was bisulphite
converted using a EZ DNA methylation gold kit (Zymo Research
Corp., Irvine, CA) according to the manufacturer’s protocol. Then,
500 ng of the bisulphate-converted DNA was assayed with an Infi-
nium Human Methylation 450 BeadChip using the Infinium HD
methylation assay kit (Illumina), which assesses the methylation
status at more than 485,000 individual CpG sites encompassing
99% of reference sequence genes and 96% of CpG islands. Each
DNA sample first underwent an overnight isothermal whole-genome
amplification step. Amplified DNA was then fragmented, precipi-
tated and resuspended. Samples were hybridized to BeadChips over-
night at 48C in an Illumina hybridization oven. Using an
automated protocol on the TecanEvo robot (Tecan Group Ltd.,
Mannedorf, Switzerland), hybridized arrays were processed through
a single-base extension reaction on the probe sequence using DNP-
or biotin-labelled nucleotides, with subsequent immunostaining.
The BeadChips were then coated, dried and imaged on an Illumina
HiScanSQ. Image data were extracted using the Genome Studio
version 2010.3 methylation module (Illumina). Beta values were
calculated at each locus (b = intensity of methylated allele/intensity
of unmethylated allele + intensity of methylated allele + 100),
followed by analysis with the R package to normalize the data. The
X and Y chromosome methylation data were excluded from the
results. Quality control inclusion valuation depended on hybridiza-
tion detection P < 0.05 (Accession number: GSE80508). Differential
methylation loci were shown in a volcano plot: red points (P < 0.05,
FC ≥ 2), and green points (P < 0.05, FC ≤ 2) indicate hypermethy-
lation and hypomethylation loci, respectively. Furthermore, a
heatmap was generated to demonstrate the indentified genes with
abnormal expression/methylation profiles. DAVID online tools were
used to implement the enrichment and pathway analysis. Venn
diagrams were used to reveal the genes with hypermethylation pro-
files: These genes are both transcription factor and target of AML1-
ETO. The hypermethylation list was derived from the differential
analysis of our 450K BeadChips, while transcription factors and
targets of AML1-ETO were from animal TFDB database (Zhang et al,
2015) and Gardini et al (2008), respectively. All statistical analyses
were carried out with R 3.2.3.
Cell transfection
For siRNA-mediated gene knock-down, 1 × 106 Kasumi-1 cells or
SKNO-1 cells were seeded into 6-well plate for overnight incubation
before transfection. miRNAs and siRNAs used in the study were
synthesized by GenePharma (Shanghai, China). The sequences of
siRNA or miRNA are provided in Appendix Table S7. Transfection
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with siRNAs and miRNAs was performed using HiPerFect (Qiagen,
Hilden, Germany) according to the manufacturer’s protocol. In brief,
for each well, 24 ll HiPerFect and 12 ll siRNA or 20 lM miRNA
were added to 400 ll serum-free RPMI-1640. The mixture was
added to cells with 400 ll complete medium and incubated for 6 h,
and then, 1.6 ml of complete medium was replenished. The final
concentration of miRNA or siRNA was 100 nM. Total RNA and
protein were prepared 48 h after transfection and subjected to qRT–
PCR or Western blot analysis. Transfection efficiency was deter-
mined using FAM-labelled control RNA by a FACScalibur flow
cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). This
reagent yielded at least 90% transfection efficiency.
For gene overexpression, 2 × 105 293 T cells were seeded into
a 6-well plate for overnight incubation before transfection. Cells
were transfected with a total of 0.5 lg expression plasmids or the
corresponding empty vectors using LipofectamineTM 2000 reagent
(Life Technologies) as per the manufacturer’s instruction. For co-
transfection experiments, the total amount of DNA or siRNA was
kept the same between the individual gene and co-transfection
groups by adding equal amounts of empty-vector or negative
control.
THAP10-expressing lentivirus preparation and transduction
Lentiviruses expressing EGFP and THAP10 were purchased from
HanBio (www.hanbio.net). For lentivirus constructs, the CDS of
THAP10 was inserted into hU6-MCS-PGK-EGFP lentiviral vectors
(Hanbio, Shanghai, China). The recombinant lentiviruses were
produced by co-transfection of 293T cells with the plasmids PSPAX2
and PMD2G with LipoFiterTM (Hanbio, Shanghai, China). Lentivirus-
containing supernatants were harvested 48 h after transduction and
filtered through 0.22-lm cellulose acetate filters (Millipore, USA).
Recombinant lentiviruses were then concentrated by ultracentrifuga-
tion (2 h at 50,000 × g). To establish stable cell lines, Kasumi-1 cells
were transduced with lentiviral vector with or without THAP10 at
an MOI of approximately 100 in the presence of 5 lg/ml polybrene.
Approximately 48 h after transduction, the medium was changed,
and puromycin was added for selection of stable transduced cells.
Puromycin-resistant colonies were selected for 3 weeks and then
expanded. Gene modification via lentiviral delivery was confirmed
by Western blot analysis.
Chromatin immunoprecipitation (ChIP)
Three biological replicate ChIP-seq experiments were conducted for
the specific detection of AML1-bound genomic regions on THAP10
and miR-383 promoters according to standard procedures with
several modifications. Briefly, cross-linked chromatin from approxi-
mately 5–10 × 107 SKNO-1, SKNO-1-siA/E, U937 and U937-A/E
cells was prepared and fragmented to an average size of approxi-
mately 200 bp by 30–40 cycles of sonication (30 s each) in 15 ml
tubes using the Bioruptor UCD-200 sonicator (Diagenode). For
immunoprecipitation, AML1 (sc-8563, Santa Cruz Biotechnology),
ETO (sc-9737, Santa Cruz Biotechnology), HDAC1 (ab7028,
Abcam), DNMT1 (ab13537, Abcam), DNMT3a (ab13888, Abcam),
DNMT3b (ab13604, Abcam) and p300 (ab14984, Abcam) antibodies
were added to 12 ml of diluted, fragmented chromatin. Nonimmu-
nized rabbit serum served as a control. ChIP using the normal
mouse IgG (Abcam) antibody was performed on naked and soni-
cated DNA extracted from the same cell samples and assayed using
the EZ-ChIPTM Chromatin Immunoprecipitation kit (Millipore) as
per the manufacturer’s instructions. Genomic THAP10 and pre-
miR-383 upstream regions close to the putative AML1-binding
site were amplified. Primer sequences are shown in Appendix
Table S7. GAPDH served as a control for nonspecific precipitated
sequences.
Immunoprecipitation and Western blot analysis
Kasumi-1 cells were treated with or without C646 (10 and 20 lM)
for 24 h, after which cells were lysed in RIPA buffer containing
1 mM DTT, 1 lg/ml DNase I and a proteinase inhibitor cocktail
(Roche) and then incubated on ice for 30 min. Anti-ETO agarose
(Santa Cruz Biotechnology) was used for immunoprecipitation
assays. For Western blot analysis, protein samples were separated
by electrophoresis on denaturing 10% SDS–PAGE gels and blotted
to PVDF membranes (Millipore). Immunoblotting was performed
using monoclonal antibodies, including anti-AML1 (MABD126,
Calbiochem), anti-p-Tyr (sc-51688, Santa Cruz Biotechnology) and
anti-Ac-histone H3 (Lys9/14, sc-8655, Cell Signalling Technology).
Anti-b-actin (sc-47778, Santa Cruz Biotechnology) was used as load-
ing control. The proteins were visualized by the ECL method (Amer-
sham Biosciences).
Transactivation assays
DNA fragments were amplified by PCR from human genomic DNA.
Primer sequences are shown in Appendix Table S7. All fragments
were inserted in pGL3-LUC reporter vectors (Promega). Various
mutants were generated using a QuikChange Lightning Site-Directed
Mutagenesis kit as per the manufacturer’s instructions (Quik-
Change, Agilent Technologies). All constructs were verified by DNA
sequencing. 2 × 105 HEK293T cells were plated in 24-well plates
and transiently co-transfected by SuperFect (Qiagen) with 10, 50 or
100 ng of pcDNA3 vectors with or without AML1-ETO cDNA,
together with 400 ng of the LUC reporter constructs as described
above. Co-transfection with a pRL-TK Renilla luciferase reporter
vector (Promega) was used as an internal control. Cells were
harvested at 48 h post-transfection and analysed using the Dual
Luciferase Assay (Promega) as per the manufacturer’s instructions.
Bisulphite sequencing assay
Bisulphite sequencing assays were performed to examine the methy-
lation status of the CpG dinucleotides within the promoter region of
the THAP10 gene, using EpiTect Bisulfite kit (Qiagen) as per the
manufacturer’s instructions. The assay was performed using 1 lg of
bisulphite-treated genomic DNA from the indicated cell lines and
blasts from untreated patients. After bisulphite conversion
performed with EpiTect Bisulfite kit (Qiagen) as previously
described (Yu et al, 2005; Li et al, 2013b), the fragments of interest
were amplified. Primer sequences are shown in Appendix Table S7.
PCR products were gel-purified and cloned into the pGEM-T vector
systems (Promega). Individual bacterial colonies were used for PCR
using vector-specific primers, and PCR products were sequenced for
the analyses of DNA methylation.
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Luciferase assays for reverse screening the miRNAs
regulating THAP10
To screen the miRNAs that directly regulate expression of THAP10,
the 30-UTR or its mutant was cloned into a modified pGL-3 control
vector downstream of the coding sequence of luciferase. The trans-
fection mixtures contained 100 ng of firefly luciferase reporter and
400 ng of plasmids expressing miR-383 primary transcripts, derived
from a constructed miRNA expression library. Transfection with
pRL-TK (Promega) was used as an internal control. The firefly luci-
ferase activities were analysed using the Dual Luciferase Assay
(Promega) at 48 h after transfection.
Microarray analysis and functional enrichment of differentially
expressed gene (DEGs)
Total RNA was isolated from Kasumi-1 cells after transduction
with lentivirus expressing THAP10 or control using an RNeasy
Mini kit (QIAGEN) according to the protocol. RNA quality,
concentration and integrity were assessed by an Agilent 2100
Bioanalyzer. Sample labelling, microarray hybridization and wash-
ing were performed as per the manufacturer’s instructions.
Briefly, total RNA was transcribed to double-stranded cDNA,
synthesized into cRNA and labelled with cyanine 3-CTP. The
labelled cRNAs were then hybridized onto the microarray. After
washing, the arrays were scanned by the Agilent Scanner G2505C
(Agilent Technologies). Gene expression was analysed with Affy-
metrix U133 plus2.0 Human Gene Expression Arrays (Affymetrix
Technologies). Data collection and analysis were performed
according to the protocols by the Gene Biotechnology Corporation
(Shanghai, China). DEGs of three independent experiments were
used for biological process enrichment with Gorilla, an online
gene ontology analyser. In addition, DEGs were used for pathway
enrichment using DAVID functional annotation bioinformatics
microarray.
Cell differentiation, apoptosis and colony-forming analysis
Cell differentiation was evaluated by morphological examination of
Wright-Giemsa-stained cytospins using light microscopy. Cells
were also stained with anti-CD11b (BD Biosciences PharMingen)
and then subjected to flow cytometric analysis (a minimum of
50,000 events were collected for each sample) by FACScan (Becton
Dickinson) using CellQuest software (Becton Dickinson) for data
acquisition and analysis. For cell proliferation assays, cells post-
transfection were seeded into 96-well plates (5,000 cells/well), and
cell proliferation was then assessed using the CCK-8 kit (Dojindo,
Japan) as per the manufacturer’s instructions. Briefly, 10 ll of
CCK-8 solution was added to the cell culture and incubated for an
additional 4 h. Absorbance was determined at 450 nm wavelength.
For apoptosis analysis, cells were stained with Annexin V and
7AAD (BD Biosciences) and analysed by a FACSCalibur flow
cytometer (Becton Dickinson). Colony formation assays were
performed using the methylcellulose H4230 culture system (Stem
Cell Technologies) as per the manufacturer’s instructions. After
incubation for 10 days at 37°C and 5% CO2 in a humidified atmo-
sphere, colonies of > 50 cells with morphological haematopoietic
characteristics were counted.
Animal studies
BALB/c nude female mice (5 weeks old and weight > 15 g) were
utilized. All mice used in this study were bred and maintained
in a pathogen-free environment. Splenectomy was performed at
least 10 days before inoculation. After the mice recovered from
the incisions, general irradiation at a dose of 400 cGy was
performed at 24 h before tumour cell inoculation. The mice were
then randomly divided into two groups. Xenograft models were
established by subcutaneous injection into the right flank with
2 × 107 Kasumi-1 cells (n = 4) or Kasumi-1-THAP10 cells (n = 5).
The mice were sacrificed on day 28, and tumour weights were
measured. A xenograft model was also established by subcuta-
neous injection with 2 × 107 SKNO-1 cells into the right flank of
nude mice. Tumour size was measured daily until it reached
50 mm3, after which 5 lg of synthetic miR-383 or scramble
diluted in Lipofectamine solution (Invitrogen) with a total
volume of 100 ll was injected directly into tumours on days 1,
3, 7 and 10. Tumours were measured on the day of the first
treatment and 4 days after the last treatment when the animals
were sacrificed. Necropsies were performed, and tumours were
weighed. Tumour volumes were calculated using the equation V
(mm3) = A×B2/2, where A is the longest diameter and B is the
perpendicular diameter.
The paper explained
Problem
Aberrant distribution of promoter DNA methylation occurring in speci-
fic and distinct patterns has been shown to be a universal feature in
t(8;21) AML patients. However, the mechanisms that mediate these
aberrant methyl cytosine patterns have not been defined.
Results
We conducted a large-scale DNA methylation profiling study and
found strong evidence that AML1-ETO contributes to aberrant
promoter DNA methylation patterning in t(8;21) AML. We found that
the promoter DNA methylation signature of t(8;21) AML blasts differs
from those of normal CD34+ bone marrow cells and non-t(8;21) AMLs.
This signature contains 408 differentially methylated genes, many of
which are involved in cancer pathways and myeloid leukaemia. Then,
database systematic survey and differential methylated regions (DMR)
analysis were performed, which demonstrated that a novel hyperme-
thylated zinc finger-containing protein, THAP10, is a target gene and
can be epigenetically suppressed by AML1-ETO at the transcriptional
level in t(8;21) AML, and suppression of THAP10 predicts a poor clinical
outcome. Our findings also showed that THAP10 is a bona fide target
of miR-383 that can be epigenetically activated by AML1-ETO. In this
study, we demonstrated that epigenetic suppression of THAP10 is the
mechanistic link between AML1-ETO fusion proteins and tyrosine
kinase cascades. In addition, we showed that THAP10 is a nuclear
protein that inhibits myeloid proliferation and promotes differentia-
tion both in vitro and in vivo.
Clinical impact
Our results identified AML1-ETO/THAP10/miR-383 as a novel epigenetic
mini-circuitry in t(8;21) AML, thereby providing a new insight into the
mechanism of AML1-ETO in driving leukaemogenesis. It also offers an
opportunity to develop THAP10 and miR-383 as novel biomarkers and
therapeutic targets in this AML subtype. Finally, genome-wide DNA
methylation profiling is a powerful tool for characterization and clini-
cal stratification of AML and warrants attention in clinical practice.
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Statistical analysis
SPSS 13.0 software was used to analyse the data. Wilcoxon
signed-rank test was performed to determine the differences in
THAP10 and miR-383 expression in clinical samples. Seventy-six
patients were grouped into quartiles according to THAP10 expres-
sion levels and divided into high (THAP10-H, n = 56) and low
(THAP10-L, n = 20) groups based on the trend observed in clinical
outcome after performing a Cox regression analysis of event-free
survival (EFS) and overall survival (OS) with THAP10 quartile
grouping as the independent variable. Multivariate survival
analysis was carried out using a Cox regression model. Student’s
t-test was used to determine the statistical significance of experi-
mental variables, and P-values < 0.05 were considered statistically
significant.
Expanded View for this article is available online.
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